Diabetes Patients On Metformin Show Better Lipid Profile

Chinese researchers found that type 2 diabetes patients taking metformin – one of the first lines of defense in the treatment of the disease – attained a better overall lipid profile compared with those who took glipizide. That’s important news for those with type 2 taking metformin, since 60 percent of all type 2 deaths are related to cardiovascular disease, and higher levels of lipids,

Read more

Once-Weekly Tanzeum for Type 2s Now Available

Tanzeum (albiglutide), a once-weekly injectable drug for type 2s from GSK (GlaxoSmithKline), USA is now available at pharmacies throughout the United States. The FDA approved U.S. sales on April 15. The drug is a glucagon-like peptide-1 receptor agonist (GLP-1) that can be used in conjunction with other type 2 drugs. GLP-1s work by inducing the pancreas to produce more insulin when blood sugar levels begin

Read more

Eylea Earns FDA Approval To Treat Diabetic Macular Edema

The U.S. Food and Drug Administration has approved the eye drug Eylea for the treatment of diabetic macular edema, according to the drug makers Regeneron Pharmaceuticals, Inc. Diabetic macular edema (DME) is a common complication for those with diabetes. Of the 29.1 million Americans with diabetes, 1.5 million have been diagnosed with DME. This occurs when the blood vessels of the retina are damaged due

Read more

New Device Spots Early Signs Of Diabetic Autonomic Neuropathy

Diabetic autonomic neuropathy, a common side effect of diabetes that is linked to a wide range of complications including digestive issues, erectile dysfunction, paralysis of the bladder and intestinal damage, is not only difficult to treat, it’s also difficult to diagnose. Currently doctors rely on changes in digestive speed, heart rate and blood pressure to detect autonomic neuropathy, which puts limits on how early a

Read more